What Did This CEO Just Do with Personal Shares of Genomic Health (GHDX)?


Yesterday, the President & CEO of Genomic Health (GHDX), Kimberly Popovits, sold shares of GHDX for $166.5K.

This is Popovits’ first Sell trade following 9 Buy transactions. In addition to Kimberly Popovits, one other GHDX executive reported Sell trades in the last month.

See today’s analyst top recommended stocks >>

Based on Genomic Health’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $105 million and quarterly net profit of $8.91 million. In comparison, last year the company earned revenue of $92.63 million and had a GAAP net loss of $3.78 million. GHDX’s market cap is $2.44B and the company has a P/E ratio of 101.58. Currently, Genomic Health has an average volume of 530.7K.

Based on 6 analyst ratings, the analyst consensus is Hold with an average price target of $80.60, reflecting a 17.5% upside.

In the last 30 days, insiders have sold $166.5K worth of GHDX shares and purchased $315.7K worth of GHDX shares. The insider sentiment on Genomic Health has been positive according to 142 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Kimberly Popovits’ trades have generated a 29.3% average return based on past transactions. DailyInsider proprietary algorithm detects trades by the most influential insiders and selects attractive trading opportunities daily. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Genomic Health, Inc. engages in the provision of genomic-based diagnostic tests. Its tests analyze the underlying biology of cancers, allowing physicians and patients to make individualized treatment decisions. The firm uses a platform which translates a massive amount of clinical and genomic data into clinically actionable results for treatment planning.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts